Ahmed Aboulenein

WASHINGTON, (Reuters) – The U.S. Congress is unlikely to be able to reduce the insulin cost for over a million Americans down to $35 per monthly as they approach November elections. This will complicate bipartisan support and health policy experts.

The March bill by the U.S. House of Representatives set a $35 ceiling on monthly insulin out-of-pocket costs for individuals with insurance. A larger bill is being drafted by senators that will also provide an incentive to drugmakers to reduce their prices.

To move forward, both houses need to pass the same legislation.

The Democratic-backed legislation was initially seen as more likely to gain the support needed, because it didn’t require pharmaceutical companies to reduce prices. This would have been a fight that the industry would have waged. Some Republicans support reforming drug pricing.

Reuters was told by health policy experts, sources from the pharmaceutical industry, patient advocates, and congressional staffers that insulin legislation is facing significant hurdles. Some reported that Democrats were still trying to secure support from 10 Republicans in Senate to pass the bill.

Ipsita, the managing director of research firm Capitol Street, stated that “as we get closer and closer towards the summer, and the election, there seems like there might not be much appetite for Democrats to win going into the Elections.”

The American Diabetes Association estimates that around 8.4 Million of 37.9 million American diabetics use insulin.

According to a report by IQVIA on 2021 drug prices, one in five Americans is liable for more than $35 per monthly. The rest of us pay around $23 per month. The District of Columbia and 20 other states have already established caps for monthly out-of-pocket insulin costs. According to the ADA, $35 is the minimum cap in 9 of these states and D.C.

This bill will help approximately 1.7 million people with Medicare or private insurance who pay over $35 per month for insulin due to their geographic location or their specific insulin needs.

Laura Marston (co-founder) of the advocacy group The Insulin Initiative stated that while the bill wouldn’t have reduced the copays of about 20% of diabetic patients, it would not have had any effect on her organization.

According to her, she stated that “it’s not a setback for our fight against insulin co-pays and the price cap”

According to 2020 Commonwealth Fund research, 17% to 6,000,000 insulin users aged 18-64 were either uninsured, or did not have coverage. A third of this group spent $900 per month on life-sustaining medicine, while the other third paid full price.

Many people have had to ration or skip insulin, putting their health at risk.

PHRMA VS AHIP

PhRMA and the insulin producers have supported the legislation. The legislation was supported by three companies Sanofi (NASDAQ:) SA (NYSE:) Eli Lilly (NYSE 🙂 and Co (NYSE 🙂 account for 90% of the insulin market, which was created in the 1920s.

Shawn O’Neail, executive at Eli Lilly, stated that a $35 copay cap would be an elegant solution for people to afford insulin.

O’Neail, O’Neail, and other industry sources stated that insurance companies would need to pass on the discounts received from drugmakers to patients instead of integrating them into the monthly premium price.

AHIP is the largest trade association in the insurance industry. It stated that a cap on co-pays would cause a cost shift, which would lead to higher premiums.

CVS Health Corp. (NYSE:) Cigna Corp UnitedHealth Group Inc (NYSE) and UnitedHealth Group Inc(NYSE:), are two of the biggest managers of prescription and health insurance benefits.

Nonpartisan Congressional Budget Office (CBO), has calculated that a $35 copay will cost the U.S. $20 billion in 10 years, as government-sponsored Obamacare and Medicare premiums rise.

CBO also stated that higher premiums for private insurance would result in lower wages and lower tax revenue.